FDA Reviews and Approvals, Commercialization, Integrations, and Top-Line Results - Research Report on Bristol-Myers Squibb,

   FDA Reviews and Approvals, Commercialization, Integrations, and Top-Line
     Results - Research Report on Bristol-Myers Squibb, Medtronic, Boston
                   Scientific, Varian, and Rockwell Medical

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 17, 2013

NEW YORK, July 17, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting
Bristol-Myers Squibb Company (NYSE: BMY), Medtronic, Inc. (NYSE: MDT), Boston
Scientific Corporation (NYSE: BSX), Varian Medical Systems, Inc. (NYSE: VAR),
and Rockwell Medical, Inc. (NASDAQ: RMTI). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Bristol-Myers Squibb Company Research Report

On July 11, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb)
announced that the US Food and Drug Administration (FDA) has accepted for
review a Supplemental New Drug Application (sNDA) for Eliquis (apixaban).
Bristol-Myers Squibb reported that Eliquis (apixaban) is for the prophylaxis
of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in
adult patients who have undergone hip or knee replacement surgery. The Company
also reported that the Prescription Drug User Fee Act (PDUFA) goal date for a
decision by the FDA is March 15, 2014. The Full Research Report on
Bristol-Myers Squibb Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


Medtronic, Inc. Research Report

On July 11, 2013, Medtronic, Inc. (Medtronic) announced the global market
introduction of the CD HORIZON SOLERA Spinal System Sagittal Adjusting Screw
(SAS), which may be used in the surgical correction of complex spinal
pathologies. According to Medtronic, the SAS features a fixed head made of
cobalt chrome that contains a sliding saddle which gives surgeons the ability
to position the SAS in the natural kyphotic (outward) and lordotic (inward)
curves of the spine. Doug King, Senior Vice President and President of
Medtronic Spinal at Medtronic, said, "The Sagittal Adjusting Screw is another
key element in enhancing the capability of our CD HORIZON SOLERA pedicle
fixation system." King added, "It brings new innovation to the market and
extends our industry-leading portfolio of spinal therapies." The Full Research
Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:


Boston Scientific Corporation Research Report

On July 12, 2013, Boston Scientific Corporation (Boston Scientific) announced
that it has received U.S. Food and Drug Administration 510(k) clearance and CE
Mark approval for the Guidezilla Guide Extension Catheter and has launched the
device in the US and Europe. Kevin Ballinger, President of Interventional
Cardiology at Boston Scientific, stated, "Boston Scientific is committed to
delivering innovative technologies such as the Guidezilla device that enable
physicians to improve outcomes for patients undergoing complex coronary
interventions." Ballinger continued, "The Guidezilla guide extension catheter
is a specialty device that provides physicians another compelling tool to help
treat difficult lesions." The Full Research Report on Boston Scientific
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Varian Medical Systems, Inc. Research Report

On July 8, 2013, Varian Medical Systems, Inc. (Varian) announced that it has
successfully integrated its Eclipse treatment planning system with Elekta
linear accelerators to deliver VMAT treatments at Kantonsspital St. Gallen in
Switzerland. Dr. Ludwig Plasswilm, Chief of Radiation Oncology at
Kantonsspital St. Gallen, commented, "Physicists at our department worked on
the development of this new approach with Varian, which has demonstrated its
commitment to open architecture for clinical systems, and we have now seen
successful integration of Eclipse with our treatment machines." Plasswilm
added, "We have now initiated more advanced volumetric treatments and our
experience so far is that the integration is very good with a natural
workflow. We haven't experienced any problems and are delighted to be the
first in the world to integrate these systems for the benefit of our
patients." The Full Research Report on Varian Medical Systems, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Rockwell Medical, Inc. Research Report

On July 11, 2013, Rockwell Medical, Inc. (Rockwell Medical) announced top-line
results from its long-term CRUISE-1 Phase 3 efficacy study of SFP. Rob
Chioini, Founder, Chairman, and CEO of Rockwell Medical, said, "We are
thrilled with the successful results of this CRUISE-1 efficacy study. In
addition to demonstrating statistical significance and meeting the primary
efficacy endpoint, the data show that in place of IV iron, SFP is a safe and
effective iron replacement therapy that consistently maintains hemoglobin
levels without increasing iron stores. These successful results, coupled with
the recent positive PRIME study data demonstrating SFP's ability to
significantly reduce ESA use, support our belief that SFP will set a new
paradigm in iron therapy treatment for hemodialysis patients. We believe SFP
is positioned to become the new standard of care in iron therapy. We
anticipate confirmatory and successful results from the CRUISE-2 trial, which
is nearing completion." The Full Research Report on Rockwell Medical, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.